2025 Q3 -tulosraportti
47 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
925
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | AVA | NON | ||
| 57 | NON | AVA | ||
| 20 | NON | NON | ||
| 500 | NON | NON | ||
| 50 | AVA | NON |
Ylin
12,05VWAP
Alin
11,2VaihtoMäärä
0,6 52 890
VWAP
Ylin
12,05Alin
11,2VaihtoMäärä
0,6 52 890
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
Alle minuutti sittenAlle minuutti sittenJeg har lavet et narrativ/beskrivelse af Curasight set fra et investorperspektiv (for fuld dokumentation henvises der til Master og Appendiks i tidligere delt materiale) Markedets konsensus synes at være: “Fase I, topline i 2026 - der er god tid.” Efter min vurdering er det en stor fejllæsning af virkeligheden. Curasight forventer at have rekrutteret alle seks patienter i Fase I inden for de kommende måneder, med topline i Q2 2026 – sandsynligvis primo i Q2. Forløbet indikerer lav klinisk og operationel friktion. Samtidig oplyser ledelsen, at man er engageret sig i strategiske drøftelser frem mod næste værdiskabende trin, som er efter Fase I. Mit klare bud er, at dialoger med tunge Big Pharma-aktører allerede har fundet sted i forbindelse med JPM, under NDA og med deling af ikke-offentlige data, både for FPD og sandsynligvis også 2. patient. På dette stadie kigger Big Pharma ikke på slutpunkter, men på om de grundlæggende forudsætninger er på plads: ✔ Target-validering i mennesker ✔ Retention til dosimetri ✔ Ingen tidlige sikkerheds- eller toksicitetsadvarsler ✔ Et program uden friktion ✔ En disciplineret og datadrevet ledelse 👉Det eneste åbne spørgsmål er varians og reproducerbarhed (patient 3–6). Bottom line: Det næste værdiskabende skridt for Curasight er ikke nødvendigvis topline resultater. I theranostics har historien gentagne gange vist, at værdiskabelsen lige så vel kan komme i form af en strategisk partneraftale, en optioneret struktur - eller ganske enkelt ved, at en Big Pharma-beslutning allerede er truffet, længe før markedet bliver opmærksom på den. Markedet venter på topline --> Big Pharma venter på mønstre. Link til narrativet/beskrivelsen: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link --------------------------------------------------------------------------- Disclaimer: Dette er ikke en købsanbefaling. Materialet er udarbejdet udelukkende til eget brug og refleksion. Jeg ejer selv aktier i Curasight.
·23 t sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?
·1 päivä sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.- ·2 päivää sittenExciting now. Whether one has more to deploy here and now - or if one must prepare for a spring that might resemble autumn. Slight quiet, pipeline intact but no new ones are really picking it up. How low can it trickle. Wildly many possible triggers, with emphasis on possible. The market awaits. Exciting if it stays in 11,5-12,5 or if it has to go further down - in the autumn it didn't handle it super well and one entered a 2 month stretch that meant almost -35% down. Without the case itself having changed - and the company genuinely does what they say they do. Technically a bit sad to see that a similar fall would mean hitting this small dilution that looms - one must hope it never comes to that.·2 päivää sittenI have added a bit to today's fall today; latest news (and possibility for new partner agreement within x number of weeks/months) is not priced in imo... That the price has risen considerably in the last 6mdr is in my opinion irrelevant; summer's capital increase forced it down.·2 päivää sittenNo; they have just completed a directed issue in December, as well as received money via loans; they are currently very strong and have announced that they And with potential milestone payments and a new partner agreement within the next months, more will be added to the coffers. See, among other things, here: "The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026." https://www.inderes.dk/releases/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-164-million-and-has-entered-into-a-new-loan-facility
- ·2 päivää sittenNew Q&A with Ulrich K: https://biostock.se/2026/01/curasight-rapporterer-uppmuntrande-preliminara-data-fran-utreat-fas-i-studie/?fbclid=Iwb21leAPVhR5jbGNrA9WEvWV4dG4DYWVtAjExAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHkni-JNxCdWBBmbeKyBoULP1jPDSsEQAaEkZf7e8chH8VAXDuG1qVrjWduXh_aem_uzSX_Xt1O6DcX3pkdfnuHA Excerpt from the article: "We are very focused on progressing our clinical efforts for uTREAT and completing the Phase 1 glioblastoma trial. In parallel, we are strengthening our regulatory preparedness, continuing to expand the clinical and translational data package, and engaging in strategic discussions to ensure we are well-positioned for the next value-inflection points following data read-out." 🙌🙌👏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
47 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- Alle minuutti sittenAlle minuutti sittenJeg har lavet et narrativ/beskrivelse af Curasight set fra et investorperspektiv (for fuld dokumentation henvises der til Master og Appendiks i tidligere delt materiale) Markedets konsensus synes at være: “Fase I, topline i 2026 - der er god tid.” Efter min vurdering er det en stor fejllæsning af virkeligheden. Curasight forventer at have rekrutteret alle seks patienter i Fase I inden for de kommende måneder, med topline i Q2 2026 – sandsynligvis primo i Q2. Forløbet indikerer lav klinisk og operationel friktion. Samtidig oplyser ledelsen, at man er engageret sig i strategiske drøftelser frem mod næste værdiskabende trin, som er efter Fase I. Mit klare bud er, at dialoger med tunge Big Pharma-aktører allerede har fundet sted i forbindelse med JPM, under NDA og med deling af ikke-offentlige data, både for FPD og sandsynligvis også 2. patient. På dette stadie kigger Big Pharma ikke på slutpunkter, men på om de grundlæggende forudsætninger er på plads: ✔ Target-validering i mennesker ✔ Retention til dosimetri ✔ Ingen tidlige sikkerheds- eller toksicitetsadvarsler ✔ Et program uden friktion ✔ En disciplineret og datadrevet ledelse 👉Det eneste åbne spørgsmål er varians og reproducerbarhed (patient 3–6). Bottom line: Det næste værdiskabende skridt for Curasight er ikke nødvendigvis topline resultater. I theranostics har historien gentagne gange vist, at værdiskabelsen lige så vel kan komme i form af en strategisk partneraftale, en optioneret struktur - eller ganske enkelt ved, at en Big Pharma-beslutning allerede er truffet, længe før markedet bliver opmærksom på den. Markedet venter på topline --> Big Pharma venter på mønstre. Link til narrativet/beskrivelsen: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link --------------------------------------------------------------------------- Disclaimer: Dette er ikke en købsanbefaling. Materialet er udarbejdet udelukkende til eget brug og refleksion. Jeg ejer selv aktier i Curasight.
- ·23 t sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?
- ·1 päivä sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.
- ·2 päivää sittenExciting now. Whether one has more to deploy here and now - or if one must prepare for a spring that might resemble autumn. Slight quiet, pipeline intact but no new ones are really picking it up. How low can it trickle. Wildly many possible triggers, with emphasis on possible. The market awaits. Exciting if it stays in 11,5-12,5 or if it has to go further down - in the autumn it didn't handle it super well and one entered a 2 month stretch that meant almost -35% down. Without the case itself having changed - and the company genuinely does what they say they do. Technically a bit sad to see that a similar fall would mean hitting this small dilution that looms - one must hope it never comes to that.·2 päivää sittenI have added a bit to today's fall today; latest news (and possibility for new partner agreement within x number of weeks/months) is not priced in imo... That the price has risen considerably in the last 6mdr is in my opinion irrelevant; summer's capital increase forced it down.·2 päivää sittenNo; they have just completed a directed issue in December, as well as received money via loans; they are currently very strong and have announced that they And with potential milestone payments and a new partner agreement within the next months, more will be added to the coffers. See, among other things, here: "The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026." https://www.inderes.dk/releases/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-164-million-and-has-entered-into-a-new-loan-facility
- ·2 päivää sittenNew Q&A with Ulrich K: https://biostock.se/2026/01/curasight-rapporterer-uppmuntrande-preliminara-data-fran-utreat-fas-i-studie/?fbclid=Iwb21leAPVhR5jbGNrA9WEvWV4dG4DYWVtAjExAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHkni-JNxCdWBBmbeKyBoULP1jPDSsEQAaEkZf7e8chH8VAXDuG1qVrjWduXh_aem_uzSX_Xt1O6DcX3pkdfnuHA Excerpt from the article: "We are very focused on progressing our clinical efforts for uTREAT and completing the Phase 1 glioblastoma trial. In parallel, we are strengthening our regulatory preparedness, continuing to expand the clinical and translational data package, and engaging in strategic discussions to ensure we are well-positioned for the next value-inflection points following data read-out." 🙌🙌👏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
925
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | AVA | NON | ||
| 57 | NON | AVA | ||
| 20 | NON | NON | ||
| 500 | NON | NON | ||
| 50 | AVA | NON |
Ylin
12,05VWAP
Alin
11,2VaihtoMäärä
0,6 52 890
VWAP
Ylin
12,05Alin
11,2VaihtoMäärä
0,6 52 890
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q3 -tulosraportti
47 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- Alle minuutti sittenAlle minuutti sittenJeg har lavet et narrativ/beskrivelse af Curasight set fra et investorperspektiv (for fuld dokumentation henvises der til Master og Appendiks i tidligere delt materiale) Markedets konsensus synes at være: “Fase I, topline i 2026 - der er god tid.” Efter min vurdering er det en stor fejllæsning af virkeligheden. Curasight forventer at have rekrutteret alle seks patienter i Fase I inden for de kommende måneder, med topline i Q2 2026 – sandsynligvis primo i Q2. Forløbet indikerer lav klinisk og operationel friktion. Samtidig oplyser ledelsen, at man er engageret sig i strategiske drøftelser frem mod næste værdiskabende trin, som er efter Fase I. Mit klare bud er, at dialoger med tunge Big Pharma-aktører allerede har fundet sted i forbindelse med JPM, under NDA og med deling af ikke-offentlige data, både for FPD og sandsynligvis også 2. patient. På dette stadie kigger Big Pharma ikke på slutpunkter, men på om de grundlæggende forudsætninger er på plads: ✔ Target-validering i mennesker ✔ Retention til dosimetri ✔ Ingen tidlige sikkerheds- eller toksicitetsadvarsler ✔ Et program uden friktion ✔ En disciplineret og datadrevet ledelse 👉Det eneste åbne spørgsmål er varians og reproducerbarhed (patient 3–6). Bottom line: Det næste værdiskabende skridt for Curasight er ikke nødvendigvis topline resultater. I theranostics har historien gentagne gange vist, at værdiskabelsen lige så vel kan komme i form af en strategisk partneraftale, en optioneret struktur - eller ganske enkelt ved, at en Big Pharma-beslutning allerede er truffet, længe før markedet bliver opmærksom på den. Markedet venter på topline --> Big Pharma venter på mønstre. Link til narrativet/beskrivelsen: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link --------------------------------------------------------------------------- Disclaimer: Dette er ikke en købsanbefaling. Materialet er udarbejdet udelukkende til eget brug og refleksion. Jeg ejer selv aktier i Curasight.
- ·23 t sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?
- ·1 päivä sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.
- ·2 päivää sittenExciting now. Whether one has more to deploy here and now - or if one must prepare for a spring that might resemble autumn. Slight quiet, pipeline intact but no new ones are really picking it up. How low can it trickle. Wildly many possible triggers, with emphasis on possible. The market awaits. Exciting if it stays in 11,5-12,5 or if it has to go further down - in the autumn it didn't handle it super well and one entered a 2 month stretch that meant almost -35% down. Without the case itself having changed - and the company genuinely does what they say they do. Technically a bit sad to see that a similar fall would mean hitting this small dilution that looms - one must hope it never comes to that.·2 päivää sittenI have added a bit to today's fall today; latest news (and possibility for new partner agreement within x number of weeks/months) is not priced in imo... That the price has risen considerably in the last 6mdr is in my opinion irrelevant; summer's capital increase forced it down.·2 päivää sittenNo; they have just completed a directed issue in December, as well as received money via loans; they are currently very strong and have announced that they And with potential milestone payments and a new partner agreement within the next months, more will be added to the coffers. See, among other things, here: "The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026." https://www.inderes.dk/releases/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-164-million-and-has-entered-into-a-new-loan-facility
- ·2 päivää sittenNew Q&A with Ulrich K: https://biostock.se/2026/01/curasight-rapporterer-uppmuntrande-preliminara-data-fran-utreat-fas-i-studie/?fbclid=Iwb21leAPVhR5jbGNrA9WEvWV4dG4DYWVtAjExAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHkni-JNxCdWBBmbeKyBoULP1jPDSsEQAaEkZf7e8chH8VAXDuG1qVrjWduXh_aem_uzSX_Xt1O6DcX3pkdfnuHA Excerpt from the article: "We are very focused on progressing our clinical efforts for uTREAT and completing the Phase 1 glioblastoma trial. In parallel, we are strengthening our regulatory preparedness, continuing to expand the clinical and translational data package, and engaging in strategic discussions to ensure we are well-positioned for the next value-inflection points following data read-out." 🙌🙌👏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
925
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | AVA | NON | ||
| 57 | NON | AVA | ||
| 20 | NON | NON | ||
| 500 | NON | NON | ||
| 50 | AVA | NON |
Ylin
12,05VWAP
Alin
11,2VaihtoMäärä
0,6 52 890
VWAP
Ylin
12,05Alin
11,2VaihtoMäärä
0,6 52 890
Välittäjätilasto
Dataa ei löytynyt